{"transactions":[{"id":693846,"issuer":{"id":573,"kind":"organization","name":"Acrivon Therapeutics, Inc.","symbol":"ACRV"},"owners":[{"id":25722,"kind":"person","name":"Levy Adam D.","position":1,"cik":"0002061876","reported_name":"Levy Adam D.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-08-06T20:34:32.000Z","date":"2026-08-04","kind":"sale","planned":false,"acquired":false,"shares":1142,"price":1.57,"value":1792.94,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares sold automatically to satisfy the mandatory tax withholding requirement upon vesting of restricted stock units."}],"balance_after":66008,"source":{"system":"sec-edgar","filing":"0000905148-26-003499","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1781174/000090514826003499/form4.xml","form_type":"4"}},{"id":769399,"issuer":{"id":573,"kind":"organization","name":"Acrivon Therapeutics, Inc.","symbol":"ACRV"},"owners":[{"id":25722,"kind":"person","name":"Levy Adam D.","position":1,"cik":"0002061876","reported_name":"Levy Adam D.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-05-20T20:30:16.000Z","date":"2026-05-18","kind":"grant","planned":false,"acquired":true,"shares":46167,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These shares represent restricted stock units (\"RSUs\"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. Of these RSUs, 16.67% of the RSUs shall vest on November 18, 2026, and the remaining RSUs shall vest in 10 substantially equal quarterly installments thereafter, in each case subject to the Reporting Person's continuous service through each such vesting date."}],"balance_after":67150,"source":{"system":"sec-edgar","filing":"0000905148-26-002552","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1781174/000090514826002552/form4.xml","form_type":"4"}},{"id":864767,"issuer":{"id":573,"kind":"organization","name":"Acrivon Therapeutics, Inc.","symbol":"ACRV"},"owners":[{"id":25722,"kind":"person","name":"Levy Adam D.","position":1,"cik":"0002061876","reported_name":"Levy Adam D.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-03-03T21:19:00.000Z","date":"2026-03-01","kind":"grant","planned":false,"acquired":true,"shares":132925,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Twenty-five percent (25%) of the shares subject to the option vest on March 1, 2027, and the remaining shares subject to the option vest in 36 substantially equal monthly installments thereafter, in each case subject to the Reporting Person's continuous service through each vesting date."}],"balance_after":132925,"derivative":{"exercise_price":1.51,"expiration_date":"2036-02-29","underlying":"Common Stock","underlying_shares":132925},"source":{"system":"sec-edgar","filing":"0000905148-26-001118","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1781174/000090514826001118/form4.xml","form_type":"4"}},{"id":936695,"issuer":{"id":573,"kind":"organization","name":"Acrivon Therapeutics, Inc.","symbol":"ACRV"},"owners":[{"id":25722,"kind":"person","name":"Levy Adam D.","position":1,"cik":"0002061876","reported_name":"Levy Adam D.","relationship":{"officer":true,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-01-16T21:01:38.000Z","date":"2026-01-14","kind":"purchase","planned":false,"acquired":true,"shares":8832,"price":1.6983,"value":14999.3856,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 above reflects the weighted average purchase price. This transaction was executed in multiple trades at prices ranging from $1.695 to $1.7086, inclusive. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares purchased at each respective price within the range set forth in footnote 1 of this Form 4."}],"balance_after":20983,"source":{"system":"sec-edgar","filing":"0000905148-26-000225","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1781174/000090514826000225/form4.xml","form_type":"4"}},{"id":1073857,"issuer":{"id":573,"kind":"organization","name":"Acrivon Therapeutics, Inc.","symbol":"ACRV"},"owners":[{"id":25722,"kind":"person","name":"Levy Adam D.","position":1,"cik":"0002061876","reported_name":"Levy Adam D.","relationship":{"officer":true,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2025-08-05T20:59:20.000Z","date":"2025-08-01","kind":"tax_withholding","planned":false,"acquired":false,"shares":1164,"price":1.26,"value":1466.64,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares withheld by the Issuer to satisfy the mandatory tax withholding requirement upon vesting of restricted stock units."}],"balance_after":12151,"source":{"system":"sec-edgar","filing":"0000905148-25-002732","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1781174/000090514825002732/form4.xml","form_type":"4"}},{"id":1178616,"issuer":{"id":573,"kind":"organization","name":"Acrivon Therapeutics, Inc.","symbol":"ACRV"},"owners":[{"id":25722,"kind":"person","name":"Levy Adam D.","position":1,"cik":"0002061876","reported_name":"Levy Adam D.","relationship":{"officer":true,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-04-03T20:30:52.000Z","date":"2025-04-01","kind":"grant","planned":false,"acquired":true,"shares":35209,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Twenty-five percent (25%) of the shares subject to the option vest on April 1, 2026, and the remaining shares subject to the option vest in 36 substantially equal monthly installments thereafter, in each case subject to the Reporting Person's continuous service through each vesting date."}],"balance_after":35209,"derivative":{"exercise_price":1.68,"expiration_date":"2035-03-31","underlying":"Common Stock","underlying_shares":35209},"source":{"system":"sec-edgar","filing":"0000905148-25-001075","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1781174/000090514825001075/form4.xml","form_type":"4"}}]}